Acacia Pharma Announces Changes to its Officers and Board of Directors

Written by: Pharmiweb editor
Published on: 16 Mar 2020

Cambridge, UK and Indianapolis, US – 2 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the following changes to its Officers and Board of Directors.


  • Christine Soden stepped down as a Director, as Chief Financial Officer and Company Secretary on 29 February 2020. Gary Gemignani now serves as the Group’s Chief Financial Officer.
  • Anne-Marie Elsley was appointed as Company Secretary for Acacia Pharma on 29 February 2020.

At the time of the Company’s Initial Public Offering (“IPO”) in March 2018, both Pieter van der Meer and Johan Kördel stated their intention to stand down from the Board at the 2019 Annual General Meeting (“AGM”). However, at that AGM the Board believed it to be in the best interests of the Company to retain their experience until such time as BARHEMSYS® (amisulpride) was approved. Having recently reached this important corporate milestone, Pieter and Johan have decided not to stand for re-election at the forthcoming AGM on 7 April 2020.

Patrick Vink, who served as Chairman for the last four years has also decided to stand down at the AGM. Scott Byrd, who has been a Director of the Company for the last three years, will be appointed by the Board as the new Chairman at the AGM.

Commenting, Scott Byrd, Chairman-elect, said: “I am very grateful to our outgoing Board members for their significant contributions to Acacia Pharma, its employees and shareholders. Without the long-term support of Pieter van der Meer (and Gilde Partners) and Johan Kordel (and Lundbeckfonden), the Company would not have gained US approval for BARHEMSYS last week. I look forward to their continuing support as significant shareholders in Acacia Pharma. I would also like to thank Patrick for his leadership through the Company’s IPO and early years as a public company, and Christine for her outstanding service and commitment over the years.”

Patrick Vink, Acacia Pharma’s outgoing Chairman, added: “I would also like to add my gratitude to the outgoing Board members who have all made such significant contributions to the Company. As Acacia Pharma moves now into the next phase of growth, we are delighted that Scott Byrd has agreed to step up as Chairman. Scott is an extremely experienced, commercially focused Director, who will ensure Acacia Pharma is well-governed and continue to provide valuable support and guidance to ensure the successful commercialization in the US of BARHEMSYS and future products.”